Sourav Kole

Paros Bio, Inc. is a private company that specializes in gene therapy for neurodegenerative diseases. The company is based in Boston, MA. The company is focused on developing a gene replacement approach to treat autosomal dominant Alzheimer's disease (ADAD). Specifically, they are working on a gene therapy that targets mutations in the presenilin 1 gene (PSEN1), which is the underlying genetic cause of ADAD.

Dolby Family Ventures (Dolby) is a venture capital firm founded in 2013. The firm is headquartered in San Francisco, California.

NeuroTherapia, Inc. discovers and develops new therapies for diseases with an underlying component of neuroinflammation. The company was founded by Mohamed Naguib Attala and Joseph F. Foss in 2015 and is headquartered in Cleveland, OH.

Libra Therapeutics, Inc. operates as biotechnology company which develops novel disease-modifying therapeutics. It focuses on the areas of amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's, Parkinson's, and Huntington's disease. The company is headquartered in San Diego, CA.

Cerevance, Inc. provides pharmaceutical services. The firm discovers new treatments for central nervous system diseases. Its platform enables to profile specific brain cell types including both neurons and glial cells in mature human brain tissue. The company was founded by Bradley A. Margus and Mark Carlton in 2016 and is headquartered in Boston, MA.

QurAlis Corp. engages in discovering and developing new therapies for amyotrophic lateral sclerosis and other neurological diseases. It offers therapeutic programs and targets, and biomarkers. The company was founded by Clifford Woolf, Kevin Eggan, Jonathan J. Fleming, and Kasper Roet and is headquartered in North Cambridge, MA.

Therini Bio, Inc. engages in research and development in the field of biotechnology. The company was founded by Katerina Akassoglou in 2016 and is headquartered in San Francisco, CA.

Mindimmune Therapeutics, Inc. develops drugs that target the immune system to treat diseases of the central nervous system. It focuses on the treatment of Alzheimer's, Huntington's disease, pain, and psychiatric disorders. The company was founded by Stevin Zorn, Frank S. Menniti, Robert B. Nelson, and Brian M. Campbell on July 12, 2016 and is headquartered in Kingston, RI.

Reservoir Neuroscience, Inc. develops novel therapeutics. It focuses on treating dysfunctional blood vessels in the brain other neurological disorders. The company was founded by Aaron Friedman in 2019 and is headquartered in Berkeley, CA.